Logo image of TDOC

TELADOC HEALTH INC (TDOC) Stock Fundamental Analysis

NYSE:TDOC - New York Stock Exchange, Inc. - US87918A1051 - Common Stock - Currency: USD

11.51  -1.18 (-9.3%)

After market: 11.41 -0.1 (-0.87%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TDOC. TDOC was compared to 39 industry peers in the Health Care Technology industry. TDOC has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, TDOC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TDOC had negative earnings in the past year.
TDOC had a positive operating cash flow in the past year.
TDOC had negative earnings in each of the past 5 years.
TDOC had a positive operating cash flow in 4 of the past 5 years.
TDOC Yearly Net Income VS EBIT VS OCF VS FCFTDOC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5B -10B

1.2 Ratios

With a Return On Assets value of -27.82%, TDOC perfoms like the industry average, outperforming 51.35% of the companies in the same industry.
With a Return On Equity value of -65.11%, TDOC perfoms like the industry average, outperforming 54.05% of the companies in the same industry.
Industry RankSector Rank
ROA -27.82%
ROE -65.11%
ROIC N/A
ROA(3y)-107.27%
ROA(5y)-66.14%
ROE(3y)-201.33%
ROE(5y)-123.36%
ROIC(3y)N/A
ROIC(5y)N/A
TDOC Yearly ROA, ROE, ROICTDOC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

1.3 Margins

Looking at the Gross Margin, with a value of 70.82%, TDOC is in the better half of the industry, outperforming 78.38% of the companies in the same industry.
In the last couple of years the Gross Margin of TDOC has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for TDOC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y0.46%
TDOC Yearly Profit, Operating, Gross MarginsTDOC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400

More info and screens

3

2. Health

2.1 Basic Checks

TDOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
TDOC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TDOC has more shares outstanding
TDOC has a better debt/assets ratio than last year.
TDOC Yearly Shares OutstandingTDOC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
TDOC Yearly Total Debt VS Total AssetsTDOC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5B 10B 15B

2.2 Solvency

TDOC has an Altman-Z score of -4.99. This is a bad value and indicates that TDOC is not financially healthy and even has some risk of bankruptcy.
TDOC has a worse Altman-Z score (-4.99) than 72.97% of its industry peers.
TDOC has a debt to FCF ratio of 7.45. This is a slightly negative value and a sign of low solvency as TDOC would need 7.45 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 7.45, TDOC is doing good in the industry, outperforming 62.16% of the companies in the same industry.
A Debt/Equity ratio of 0.66 indicates that TDOC is somewhat dependend on debt financing.
TDOC's Debt to Equity ratio of 0.66 is on the low side compared to the rest of the industry. TDOC is outperformed by 70.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 7.45
Altman-Z -4.99
ROIC/WACCN/A
WACC8.15%
TDOC Yearly LT Debt VS Equity VS FCFTDOC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5B 10B 15B

2.3 Liquidity

A Current Ratio of 1.73 indicates that TDOC should not have too much problems paying its short term obligations.
TDOC has a Current ratio (1.73) which is in line with its industry peers.
TDOC has a Quick Ratio of 1.69. This is a normal value and indicates that TDOC is financially healthy and should not expect problems in meeting its short term obligations.
TDOC has a Quick ratio of 1.69. This is comparable to the rest of the industry: TDOC outperforms 54.05% of its industry peers.
Industry RankSector Rank
Current Ratio 1.73
Quick Ratio 1.69
TDOC Yearly Current Assets VS Current LiabilitesTDOC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B

More info and screens

4

3. Growth

3.1 Past

TDOC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 95.42%, which is quite impressive.
Looking at the last year, TDOC shows a small growth in Revenue. The Revenue has grown by 0.39% in the last year.
The Revenue has been growing by 44.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)95.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.71%
Revenue 1Y (TTM)0.39%
Revenue growth 3Y33.49%
Revenue growth 5Y44.17%
Sales Q2Q%-2.99%

3.2 Future

TDOC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.53% yearly.
TDOC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.04% yearly.
EPS Next Y-343.34%
EPS Next 2Y15.77%
EPS Next 3Y10.17%
EPS Next 5Y10.53%
Revenue Next Year-1.69%
Revenue Next 2Y-1.28%
Revenue Next 3Y-0.33%
Revenue Next 5Y1.04%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TDOC Yearly Revenue VS EstimatesTDOC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B
TDOC Yearly EPS VS EstimatesTDOC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -10 -20 -30 -40 -50

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

TDOC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TDOC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TDOC Price Earnings VS Forward Price EarningsTDOC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, TDOC is valued cheaply inside the industry as 97.30% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, TDOC is valued cheaply inside the industry as 89.19% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.58
EV/EBITDA 4.85
TDOC Per share dataTDOC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.77%
EPS Next 3Y10.17%

More info and screens

0

5. Dividend

5.1 Amount

TDOC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TELADOC HEALTH INC

NYSE:TDOC (2/21/2025, 8:04:00 PM)

After market: 11.41 -0.1 (-0.87%)

11.51

-1.18 (-9.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)10-30 2024-10-30/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners83.27%
Inst Owner Change-0.14%
Ins Owners0.46%
Ins Owner Change-0.37%
Market Cap1.98B
Analysts68.48
Price Target11.03 (-4.17%)
Short Float %13.6%
Short Ratio4.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.66%
Min EPS beat(2)20.89%
Max EPS beat(2)32.44%
EPS beat(4)3
Avg EPS beat(4)17.89%
Min EPS beat(4)-3.79%
Max EPS beat(4)32.44%
EPS beat(8)6
Avg EPS beat(8)-1139.65%
EPS beat(12)9
Avg EPS beat(12)-984%
EPS beat(16)10
Avg EPS beat(16)-818.13%
Revenue beat(2)0
Avg Revenue beat(2)-1.78%
Min Revenue beat(2)-3.05%
Max Revenue beat(2)-0.51%
Revenue beat(4)0
Avg Revenue beat(4)-1.93%
Min Revenue beat(4)-3.55%
Max Revenue beat(4)-0.51%
Revenue beat(8)0
Avg Revenue beat(8)-1.66%
Revenue beat(12)0
Avg Revenue beat(12)-1.55%
Revenue beat(16)0
Avg Revenue beat(16)-1.47%
PT rev (1m)-0.87%
PT rev (3m)7.56%
EPS NQ rev (1m)-2.6%
EPS NQ rev (3m)-4.43%
EPS NY rev (1m)-0.17%
EPS NY rev (3m)-0.13%
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)-0.15%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.77
P/FCF 9.58
P/OCF 5.86
P/B 1.31
P/tB N/A
EV/EBITDA 4.85
EPS(TTM)-1.13
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)1.2
FCFY10.44%
OCF(TTM)1.96
OCFY17.05%
SpS15.04
BVpS8.76
TBVpS-1.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.82%
ROE -65.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.82%
FCFM 7.99%
ROA(3y)-107.27%
ROA(5y)-66.14%
ROE(3y)-201.33%
ROE(5y)-123.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y0.46%
F-Score6
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 7.45
Debt/EBITDA 1.94
Cap/Depr 18.49%
Cap/Sales 5.06%
Interest Coverage N/A
Cash Conversion 66.05%
Profit Quality N/A
Current Ratio 1.73
Quick Ratio 1.69
Altman-Z -4.99
F-Score6
WACC8.15%
ROIC/WACCN/A
Cap/Depr(3y)48.02%
Cap/Depr(5y)40.96%
Cap/Sales(3y)5.44%
Cap/Sales(5y)4.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.71%
EPS Next Y-343.34%
EPS Next 2Y15.77%
EPS Next 3Y10.17%
EPS Next 5Y10.53%
Revenue 1Y (TTM)0.39%
Revenue growth 3Y33.49%
Revenue growth 5Y44.17%
Sales Q2Q%-2.99%
Revenue Next Year-1.69%
Revenue Next 2Y-1.28%
Revenue Next 3Y-0.33%
Revenue Next 5Y1.04%
EBIT growth 1Y6.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year225.11%
EBIT Next 3Y49.48%
EBIT Next 5Y29.08%
FCF growth 1Y217.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.32%
OCF growth 3YN/A
OCF growth 5YN/A